A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel

• DOI: 10.1007/s10096-022-04538-w
• Publication Date: 2022-12-07T00:03:27Z
• Authors: Kordo Saeed; Nusreen Ahmad-Saeed; Rachel Annett; Gavin Barlow; Lucinda Barrett; Sara E. Boyd; Nicola Boran; Peter Davies; Harriet Hughes; Gwennan Jones; Laura Leach; Maureen Lynch; Deepa Nayar; Robert J. Maloney; Martin Marsh; Olivia Milburn; Shanine Mitchell; Lynn Moffat; Luke S. P. Moore; Michael E. Murphy; Shaan Ashk O’Shea; Fionnuala O’Sullivan; Teresa Peach; Christina Petridou; Niamh Reidy; Mathyruban Selvar...; Ben Talbot; Vanessa Taylor; Deborah Wearmouth; Catherine Aldridge
• Keywords: Medical microbiology; Microbiological culture; Guideline

Abstract Septic arthritis is a serious condition with significant morbidity and mortality, routinely diagnosed using culture. The FDA has recently approved the rapid molecular BioFire® Joint Infection Panel (BJIP) for synovial fluid. We aimed to evaluate BJIP compared culture its potential use in patient management. A multicentre retrospective evaluation of was conducted UK Ireland. Positive percent agreement (PPA) negative (NPA) were calculated between routine multidisciplinary team (MDT) discussion addressing optimal or case assay practice facilitated. Three hundred ninety-nine surplus fluid samples (~ 70% from native joints) eight centres processed addition An increased yield positive results detected (98 vs 83), giving an overall PPA 91.6% NPA 93% results. resistant markers additional organisms that could influence antibiotic choices including Neisseria gonorrhoeae Kingella kingae . MDT agreed be used, standard methods, adult children patients specialist advice based on local needs. Rapid assessed as having clinical impact Organisms not included panel may clinically limit value this test PJI.